The effect of zinc dose on anemia in non-dialysis chronic kidney diseases patients

Evaluation of the effect of zinc dose received through supplements for kidney diseases patients in Iran (Nephrovit® or Nephrotonic®) on iron stores and anemia in non-dialysis chronic kidney diseases patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100111003043N15

Enrollment

Registered

2021-08-14

Start date

2021-09-23

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with chronic kidney disease stage 3 to 5. Anemia in chronic kidney disease

Interventions

Intervention 1: In the control group, patients receive currently available supplements for kidney patients, (nephrovit or nephrotonic containing 25 mg of zinc) daily. Patients' blood samples are taken

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients aged 18-85 years, with stage 3 or more CKD according to the KDIGO guideline, who have been treated with nephrovitis or nephrotonics for more than three months, No significant changes in their diet.

Exclusion criteria

Exclusion criteria: History of chronic infection (AIDS, bacterial, fungal or parasitic infections), severe infection (sepsis) in the last month, cancer, alcohol abuse, use of anemia-inducing drugs (some antibiotics such as linezolid, cotrimoxazole, chloramphenicol and Isoniazid, routine use of nonsteroidal anti-inflammatory drugs, chemotherapy drugs, hydroxyurea, azathioprine, 6-mercaptoporin, sulfasalazine, and methotrexate), treatment with steroids or immunosuppressant, hospitalization, history of blood transfusion within 1 month prior to enrollment.

Design outcomes

Primary

Measure	Time frame
Hemoglobin level. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;Hematocrit rate. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;Ferritin level. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;The amount of serum iron. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;Plasma level of copper. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;Plasma level of zinc. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;Plasma levels of ceruloplasmin. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;MCV rate. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;TIBC rate. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.	—

Measure

Time frame

Hemoglobin level. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;Hematocrit rate. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;Ferritin level. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;The amount of serum iron. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;Plasma level of copper. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;Plasma level of zinc. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;Plasma levels of ceruloplasmin. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;MCV rate. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.;TIBC rate. Timepoint: At the beginning of the study and three months after the intervention. Method of measurement: blood test.

—

Secondary

Measure	Time frame
Mean doses of iron (oral or intravenous). Timepoint: during 1 month before the study, and during the study period. Method of measurement: Prescribed iron.;Mean doses of erythropoietin. Timepoint: during 1 month before the study, and during the study period. Method of measurement: Prescribed erythropoietin.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Nazari Taloki

Tehran University of Medical Sciences

zahra.nazari.taloki@gmail.com+98 21 6695 4709

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026